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Abstract: Migraine headaches are typically episodic in nature and may affect nearly 10% of the population. In addition to treatment,
prevention of subsequent episodes or progression to a chronic migraine state is an important therapeutic area. Topiramate is a centrally
acting medication approved for both the prevention of seizures and migraine headache. At this time, the exact mechanism of how topiramate assists in migraine prevention is unknown. Several large randomized, controlled trials have aided in establishing topiramate’s role
in migraine prevention. Despite a favorable pharmacokinetic and adverse effect profile established in clinical trials, several additional
studies, case reports and toxicology reports have demonstrated topiramate as a cause of cognitive and behavioural changes. The use of
topiramate in migraine prevention can improve a patient’s quality of life and is a cost-effective option for migraine prevention.
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Introduction

Headache is a common disorder, with an estimated
prevalence of 5 to 12% based on data obtained from
an international survey conducted in five countries.
Migraine headache occurs in 9% of the general population.1 The International Headache Society (IHS)
defines migraine without aura as a recurrent headache disorder with attacks lasting from 4 to 72 hours.
Typical characteristics include headache pain that is
unilateral, pulsatile, and of moderate to severe intensity, and symptoms are often associated with nausea,
photophobia or phonophobia. Routine physical activity can worsen the headache. Migraine with aura is
defined by the IHS as a recurrent disorder presenting
as attacks of reversible focal neurological symptoms
that usually develop gradually over 5 to 20 minutes and
continue for a duration of up to 60 minutes. Headache
with the characteristics of migraine without aura typically occur after the aura symptoms. Migraine headaches can also be classified as episodic or chronic.
Approximately 3% of patients with episodic migraine
will advance to chronic migraine in one year.2 From
both a clinical and economic perspective, data also
support the need to prevent the progression of episodic migraine to chronic migraine.3,4 Interventions
can be taken to decrease the risk for progression of
migraine from episodic to chronic.5
Topiramate was originally developed and marketed for epilepsy. It is proposed that epilepsy
and migraine share some of the same pathophysiological mechanisms including abnormal function
of voltage-gated sodium and calcium channels,
reduced GABA-mediated inhibition, and increased
glutamate-mediated excitation.6,7 Additional proposed commonalities include a low threshold for
activation of cortical hyperexcitability and genetics.8 Evidence also suggests that epilepsy and
migraine are comorbid conditions.9 The efficacy
of topiramate as an antiepileptic drug (AED) was
proven in controlled trials in the United States and
Europe. Since that time, various trials have proven
the efficacy and safety of topiramate in migraine
prevention and treatment. It is approved for prophylactic treatment of migraine by the United States
Food and Drug Administration (FDA).
The American Academy of Neurology recommends numerous therapies for the prevention of
migraines.10 It recommends initiating treatment for
156

migraine prophylaxis when a patient experiences
either recurring migraines that significantly interfere
with activities of daily living despite the use of acute
treatment; frequent headaches and a contraindication, adverse event; or overuse of the acute medications. Patients who experience unusual migraine
conditions such as migraine with prolonged aura or
a migrainous infarction are also candidates for preventive therapy.10 The guidelines include topiramate
therapy as a class III recommendation, however
numerous additional data have been published since
their recommendations in 2000.

Mechanism of action and pharmacology

The exact mechanism of topiramate is unknown, but
several activities are theorized to contribute to its efficacy for migraine prophylaxis. Since migraine and
epilepsy are thought to share various pathophysiologic
properties, it is thought that topiramate exhibits similar mechanisms of action in both disorders. During
both migraine and epilepsy, topiramate is predicted
to exhibit its action through the blockade of sodium
channels, L-type calcium channels, and also blockade
of α-amino-3-hydoxy-5-methylisoxazole-4-propionic
acid (AMPA) and kainate currents.11,12 The enhancement of gamma-aminobutyric acid (GABA)-mediated
inhibition is also a potential mechanism of topiramate in both paroxysmal disorders.13 Topiramate is
proposed to inhibit carbonic anhydrase.14 It is also
believed that topiramate prevents phosphorylation of
locations on some receptors, channels and proteins.15
The theorized pharmacologic mechanisms of
action of topiramate relate to the proposed etiology of
migraine to potentially explain its effects on the disease. Through sodium and calcium blockade, topiramate is able to modulate the abnormal function of these
channels in migraine to possibly result in decreased
neurotransmitter release and decreased blood vessel
dilatation.16,17 A decrease in GABA-mediated inhibition is thought to play a role in migraine development. The modulation of GABA receptors simply
results in an enhancement of GABA-mediated inhibition.13 An increase in glutamate-mediated excitation
is also proposed to have a key role in the development
of migraine. Therefore, the inhibition of AMPA and
kainate currents result in less excitation by inhibiting trigeminal firing.16 The inhibition of carbonic
anhydrase activity results in an overall decrease in
Journal of Central Nervous System Disease 2011:3
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e xcitatory neurotransmission and an increase of
inhibitory neurotransmission.18

Pharmacokinetics

Pharmacokinetic studies demonstrate that topiramate
has a wide therapeutic range and low interpatient
variability. Early studies of topiramate in humans
established the plasma and renal pharmacokinetic
parameters. The study examined pharmacokinetic
changes for five different doses of topiramate.19
Topiramate is rapidly absorbed with 80% bioavailability and peak plasma concentration occurring
approximately two hours after oral intake of a 400 mg
dose.20 Rate of absorption is slightly decreased when
topiramate was administered with food; however, the
decrease was not enough to produce changes of clinical importance.19
Within the blood concentration range of
0.5–250 µg/mL, topiramate is 15 to 41% bound to
human plasma proteins.20 Topiramate is not extensively metabolized, and approximately 70% of the
orally administered dose is excreted unchanged in the
urine. In patients with moderate to severe renal failure, the renal clearance was reduced by 42 to 54%.
Therefore it is recommended to decrease the starting
dose and maintenance dose by one-half in patients
with moderate to severe renal failure.20
An open-label, randomized sequence, two-period
cross-over study was conducted on 28 healthy male
volunteers in Mexico.21 The purpose of the study was
to determine the bioequivalence of two oral forms,
a generic form and a branded form, of a single,
100 mg daily dose of topiramate. Both formulations
were rapidly absorbed from the gastrointestinal tract.
Topiramate was detected in the first plasma sample
which was obtained 0.25 hours after administration.
Cmax was reported as 1.914 µg/ml for the generic product and 1.908 µg/ml for the branded one. Half-life
was 26.22 hours for the generic and 27.21 hours for
the branded. The study did not find any statistically
significant differences among the pharmacokinetic
parameters. The researchers concluded that the
generic form of topiramate was bioequivalent to the
branded form.
A small study (n = 15) examined the pharmacokinetics in pregnant women.22 Blood samples at baseline and during all trimesters were only available for
10 of the women. The researchers calculated the dose
Journal of Central Nervous System Disease 2011:3

to plasma concentration ratio (D/C) to compare levels
among study participants. At baseline, the patients’
daily dose of topiramate ranged from 100 to 400 mg.
Nine patients experienced a dose change during
pregnancy. The mean dose to concentration ratio was
37.3 L/day at baseline, 49.4 L/day, 67.5 L/day, and
65.1 L/day during the first, second, and third trimesters (The P , 0.0001 for increase from baseline). The
study participants displayed high variability among
the increased ratios. The increase in dose to plasma
concentration ratios ranged from 19 to 164%. The
authors suggest monitoring topiramate levels during
pregnancy.
In summary, topiramate has a linear relationship
between dose and plasma concentrations, low oral
clearance, a relatively long half-life and renal excretion
of unchanged drug as a major pathway for elimination.
Topiramate is almost completely absorbed from the
gastrointestinal (GI) tract and does not significantly
inhibit or induce other drug metabolizing enzymes.14
Topiramate is not extensively metabolized and it easily crosses into the CNS.23

Dosing

The recommended total daily dose of topiramate for
the treatment of migraine prophylaxis is 100 mg/day
in two divided doses. A four-week titration is recommended in order to achieve the target dose. Week
one dosing starts at 25 mg in the morning and 25 mg
in the evening. The total daily dose is increased by
25 mg per week until a total daily dose of 100 mg is
achieved.20

Clinical trials

The efficacy and safety of topiramate has been examined in multiple clinical trials for a variety of indications including seizure, alcohol withdrawal, weight
loss and migraine prophylaxis in both adult and
pediatric patients. This review is limited to its use in
migraine prophylaxis in adult patients. For a discussion of its use for other indications and in other populations, the reader is referred elsewhere.24,25
Topiramate use in migraine prophylaxis has been
studied in both placebo and active controlled trials. The
trials will be presented based on the American Academy of Neurology classification for level of evidence
(Table 1). Three large, randomized, placebo-controlled
trials have established the efficacy of topiramate in the
157
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Table 1. AAN classification of evidence for therapeutic intervention.10
Class I

Class II
Class III

Class IV

Prospective, randomized, controlled clinical trial with masked outcome
assessment, in a representative population.
The following are required:
(a) Primary outcome(s) is/are clearly defined
(b) Exclusion/inclusion criteria are clearly defined
(c) Adequate accounting for drop-outs and crossovers with numbers sufficiently
low to have minimal potential for bias
Prospective matched group cohort study in a representative population with
masked outcome assessment that meets (a)–(d) above OR a RCT in a
representative population that lacks one criteria (a)–(d).
All other controlled trials (including well-defined natural history controls or
patients serving as own controls) in are presentative population, where
outcome is independently assessed, or independently derived by objective
outcome measurement.
Evidence from uncontrolled studies, case series, case reports, or expert opinion.

prevention of migraines. The first level one evidence
trial assessed the safety and efficacy of topiramate in
migraine prevention. It was a randomized, doubleblind, placebo-controlled, multicenter trial at 49 locations within the United States.26 A total of 487 patients
were randomized into four groups: placebo (n = 117),
topiramate 50 mg/day (n = 125), 100 mg/day (n = 128)
or 200 mg/day (n = 117). Topiramate was started at
25 mg/day and increased by 25 mg/week for 8 weeks
until the maximum assigned dose given in divided
doses in the morning and evening was reached. The
primary endpoint was a decrease in mean monthly
migraine frequency from baseline until the end of
the six month treatment phase. The primary endpoint decreased significantly for the groups receiving topiramate 100 mg/day [mean ± SD, (5.4 ± 2.2 to
3.3 ± 2.9, P , 0.001)] and 200 mg/day [mean ± SD,
(5.6 ± 2.6 to 3.3 ± 2.9, P , 0.001)]. The mean change
from baseline of migraine frequency was also greater
for patients who received topiramate administered in
doses of 100 mg or 200 mg per day (P , 0.001).26
A second level one evidence trial assessed the efficacy and safety of topiramate for migraine prevention.
The randomized, double-blind, placebo-controlled
26-week study was conducted at 52 North American
clinical centers.27 The primary outcome was the
change from baseline in mean monthly migraine
frequency. A total of 483 participants were randomized to one of four groups. The groups consisted of
placebo (n = 114), topiramate 50 mg/day (n = 116),
topiramate 100 mg/day (n = 120) and topiramate
200 mg/day (n = 117). For patients receiving the
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100 mg/day of topiramate, mean migraine frequency
decreased from 5.8 ± 2.6 to 3.5 ± 3.5 headaches per
month. For patients receiving 200 mg/day, mean
migraine frequency decreased from 5.1 ± 2.0 (SD) to
3.0 ± 2.2) headaches monthly. The change from baseline was statistically significant for patients receiving
100 mg/day (P = 0.008) or 200 mg/day (P , 0.001)
doses relative to placebo. The significant decrease
in monthly migraine frequency occurred within the
first month of preventative therapy with topiramate at
doses of 100 mg/day and 200 mg/day and continued
throughout the remainder of the double-blind phase.
There was also a decrease in the number of days per
month that patients in the 100 mg/day (P = 0.01) or
200 mg/day (P = 0.005) needed acute migraine rescue
treatment.
The third level one evidence trial examined
migraine frequency after the end of prophylaxis
treatment, which is typically recommended for 6 to
9 months.28 The trial took place in 88 clinics throughout 21 countries. A total of 559 patients completed
the 26-week open-label phase of the study. A total
of 514 patients completed the 26-week randomized,
double-blind, placebo-controlled phase of the trial.
Patients were assigned to topiramate (n = 255) or placebo (n = 259).The investigators found that the mean
increase in number of migraine days before and after
topiramate discontinuation was greater in the placebo
group (1.19 days in 4 weeks, P , 0.0001) compared
to the topiramate (0.10 days, P , 0.5756) group. The
investigators also discovered that topiramate has persistent effects after discontinuation because even after
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therapy completion the number of migraine days per
month remained less than pre-treatment values. The
study participants were also given the migraine disability assessment test to assess quality of life (QOL).
The results showed that QOL was higher in patients
who continued treatment with topiramate than those
who received placebo during the second half of the
study. The authors suggest that some patients should
be given the option to continue treatment past the
6 months of standard treatment.28
A smaller trial examined the ability of topiramate
to reduce the number of headache days in chronic
migraine.29 The study design was randomized, doubleblind, placebo-controlled, parallel-group, multicenter
trial to study the efficacy of topiramate in patients
with chronic migraine with and without medication over use.29 The intent-to-treat population was
32 patients in the topiramate group and 27 patients
for the placebo group. Topiramate was titrated by
25 mg per week until the target dose of 100 mg
per day was achieved. The duration of study treatment for the topiramate group was 100 days versus
92 days in the placebo group. The investigators concluded that topiramate significantly reduced the mean
number of migraine days per month from baseline
by 3.5 ± 6.3 (SD) days. The placebo group had an
increase of 0.2 ± 4.7 days.29 A significant percentage
of patients (22%) who received topiramate had a 50%
or more reduction in mean monthly migraine days
as compared to no patients in the placebo group.29
Study participants were also given multiple migraine
related QOL questionnaires and tests. They completed the Migraine Specific Quality of Life Questionnaire (MSQ), the Headache Impact Test (HIT)
and the Migraine Disability Assessment (MIDAS)
questionnaire. No significant differences were found
between the two groups with the MSQ or HIT. The
MIDAS questionnaire reflected improvement in the
topiramate group versus placebo. This trial indicates
that topiramate is superior to placebo in reducing the
number of headache days in patients with chronic
migraine, but its effects on headache-related quality
of life were not well-established.
Two studies have been conducted that compare topiramate to propranolol. The first study is a
randomized, double-blind, parallel-group, multicenter trial that compared topiramate to placebo and
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uses propranolol as an active control. The trial was
conducted in centers throughout 13 countries.30 The
core double-blind phase of the trial consisted of an
8 week titration phase and an 18 week maintenance
phase. Subjects (n = 575) were randomized to receive
topiramate 100 mg/day (n = 139 intent-to-treat), topiramate 200 mg/day (n = 143), propranolol 160 mg/
day (n = 143) or placebo (n = 143). Topiramate also
decreased average monthly migraine frequency
by 1.6 headaches per month, compared to an average 0.8 headache decrease in the placebo group
(P = 0.011). The topiramate 100 mg/day group also
experienced a decrease in the number of days of rescue medication use, with 1.5 days fewer than baseline
with topiramate 100 mg/day compared to 0.8 days
fewer in the placebo arm. When examining the results
for mean number of migraines per month, there was
no difference between topiramate 100 mg/day and
propranolol groups.30 Unfortunately, a complete statistical comparison of the results between topiramate
and propranolol was not conducted. When considering the results of the study, the authors advise that
topiramate dosed at 100 mg/day had the best benefitrisk relationship.30
A second, relatively small trial compared low-dose
topiramate to propranolol for migraine prophylaxis.
The double-blind, randomized trial consisted of
62 patients in Iran, who were studied for a total of
8 weeks. The groups were randomized to receive
topiramate 50 mg/day or propranolol 80 mg/day.31
The patients were titrated up to these doses over a
period of 1 week. The parameters examined by the
investigators were average frequency of migraine
per month, headache intensity, and duration of each
migraine episode. Both groups reported a decrease in
all of the parameters being measured. The topiramate
group had a significantly larger reduction in intensity
of migraine. The authors conclude that low-dose topiramate is effective for migraine prophylaxis despite
larger trials that have found little to no benefit for the
50 mg/day dose of topiramate.
A prospective, observational 12 week study examined the use of topiramate for migraine prophylaxis
in the Asian population.32 Sixty subjects were started
on topiramate 25 mg daily and were titrated over four
weeks to an initial target daily dose of 50 or 100 mg.
The mean and maximum daily doses given during the
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study were 80 mg and 200 mg, respectively. The mean
number of migraine attacks decreased by 1.9 in four
weeks. The authors concluded that the effective daily
dose in some patients was as low as 25 mg.
A single randomized trial compared topiramate
and amitriptyline. This double-blind, double-dummy,
parallel-group, multicenter trial was conducted as a
26-week noninferiority trial in adult migraineurs. The
study included 32 sites across the United States. A total
of 331 subjects with episodic migraines were included
in the intention-to-treat population.33 Subjects were
divided into two groups and randomized to receive
a target dose of 100 mg/day of either topiramate or
amitriptyline. The intent-to-treat population included
172 patients for the topiramate arm and 159 patients
for the amitriptyline arm. The primary outcome of the
study, change from baseline in the number of monthly
migraines, was not different between groups. The
change in the mean monthly frequency of migraine
episodes from the baseline was not identified to be
significantly different between the two groups. There
was no difference in secondary outcomes including
changes from the prospective baseline phase to the
end of the double-blind phase in average monthly
rate of days with migraine, mean monthly headache
days, mean monthly rate of acute migraine medication
use, mean monthly migraine duration, and monthly
migraine severity. Additional secondary variables
included mean severity of migraine-associated symptoms, change in the average frequency of migraineassociated vomiting and response rates. Subjects
in the topiramate group also reported a significant
(P = 0.040) improvement in their average functional
disability scores during a migraine attack compared
with the amitriptyline group.33 The authors conclude
that topiramate 100 mg/day is as effective as amitriptyline 100 mg/day in reducing the average number of
migraine episodes per month.33
An additional trial examined the use of topiramate
for 14 months as an open-label extension of two large
trials.26,27,34 The primary goal was to demonstrate that
topiramate is effective and well-tolerated when used
up to 14 months for the prevention of migraines.34 The
study enrolled 567 patients previously enrolled in one
of the two large 26-week trials conducted in the US and
Canada. Patients either completed the entire 26-week
trial or withdrew after 4 weeks because of lack of
efficacy. The open-label extension was conducted
160

within an 8 month time period of the subject’s study
completion. A physician titrated all patients up to a safe
and effective dose. The level of titration was based on
the patient’s response. The mean daily dose during the
open-label extension of the study was 150.3 mg ± 65.7
(SD). The primary outcome was the mean change in
monthly migraine frequency throughout the 8-month
open-label extension phase from both the doubleblind baseline and the double-blind endpoint. Their
study determined that the clinically significant reduction in mean monthly migraine frequency for patients
who received topiramate 100 mg/day or 200 mg/day
during the double-blind phase continued during the
open-label extension phase. For patients receiving
100 mg/day during the double-blind phase, the mean
monthly migraine frequency decreased from 3.2 headaches at the end of the double-blind phase to 2.1 headaches at the end of the open-label phase. For patients
receiving 200 mg/day, the mean monthly migraine
frequency decreased from 3.1 to 2.1.34 Patients that
were switched from placebo or topiramate 50 mg/day
to the open-label extension topiramate dose also experienced a decrease in the average number of migraines
per month. The rates of adverse events were less
during this phase than the double-blind phase of the
studies. The authors conclude that based on their data,
topiramate has the potential to be safe and effective
when used long-term.34
In a randomized, double-blind, placebo-controlled
trial, Silberstein et al. examined the efficacy and safety
of topiramate in the treatment of chronic migraine.35
The trial consisted of 16 weeks of the double-blind
phase at 46 sites within the United States.35 A total of
328 subjects were randomized to receive placebo or
topiramate at a dose of 100 mg/day. A total of 92 subjects in the original topiramate group of 165 subjects
completed the study. A total of 90 subjects from the
original placebo group of 163 completed the doubleblind phase of treatment. The primary endpoint was
change from baseline in the mean monthly number
of migraine/migrainous days. Patients treated with
topiramate had a statistically significant (P = 0.010)
mean reduction of migraine/migrainous headache
days compared to placebo. Topiramate patients had
a mean reduction of 6.4 migraine/migrainous days
per month. Placebo patients had a mean reduction of
4.7 migraine/migrainous days per month. The most
common reason given for leaving the study early
Journal of Central Nervous System Disease 2011:3
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was listed as inadequate efficacy.35 The researchers
completed an intent-to-treat analysis for the statistical
results. The majority of this population had received
either drug or placebo for approximately 85 days.
Withdrawal from the study because of adverse events
was 10.9% of the patients from the topiramate group,
and 6.1% of patients in the placebo group. The authors
conclude that topiramate was safe and well-tolerated
in their group of patients suffering from chronic
migraine.35

Safety and tolerability

Paresethesias, fatigue, gastrointestinal side effects,
memory difficulty, and taste perversion are common
side effects with topiramate therapy. The incidence
of these side effects in patients who were receiving
100 mg per day of topiramate in one of four randomized controlled trials or the open-label extension trial
is found in Table 2.26,27,30,34,35 Only side effects with
a 10% incidence or greater are included in the table.
Additional trials either did not report an adverse effect
that occurred in 10% or more of the study population,
or a standardized dose of 100 mg per day of topiramate was not used.
During the OLE trial, upper respiratory tract infection and sinusitis occurred in 13.8% and 10.5% of
patients respectively. Data for these side effects were
not reported in the three large randomized controlled
trials. Renal calculi were reported in a total of
10 patients out of all three randomized controlled trials. Warnings and precautions associated with topiramate therapy include metabolic acidosis, acute myopia
and secondary angle closure glaucoma, oligohydrosis
and hyperthermia, cognitive-related dysfunction and
psychiatric disturbances.20 The incidence of metabolic

acidosis in controlled clinical trials was 15% for 50 mg
per day dose. The incidence for cognitive dysfunction
is 22% at a daily dose of 100 mg of topiramate.20
Precaution should be taken when a patient receives
both topiramate and valproic acid. The use of both of
these medications at the same time is linked to hyperammonemia with or without encephalopathy. At the
most prevalent dosing range, topiramate was not
shown to significantly interact with oral contraceptives containing ethinylestradiol or norethidrone.15
Studies have been conducted to examine additional
drug-drug interactions.36
Upon initial approval, topiramate was designated
as Pregnancy Category C by the United States Food
and Drug Administration (FDA). In March 2011,
the FDA changed the designation to Pregnancy
Category D indicating that positive evidence of
human fetal risk exists, but that the potential benefits
of the use during pregnancy may outweigh the risks
in some women.20,37 New data emerged from the
North American Antiepileptic Drug Pregnancy Registry indicating an increased risk of cleft lip and cleft
palate in babies born to women who took topiramate
during pregnancy, especially during the first trimester. The prevalence of oral clefts in infants exposed
to topiramate monotherapy is 1.4%, while the prevalence in infants exposed to other antiepileptic drugs
is 0.38 to 0.55%. The prevalence in infants of mothers without epilepsy or treatment with antiepileptic
drugs is 0.07%.37 Data from the UK Epilepsy and
Pregnancy Register also validate the results that
were reported in the United States.38 Four out of 178
(2.2%) live births that were exposed to topiramate
during the first trimester resulted in oral clefts. Topiramate is also associated with a low birth weight.

Table 2. Adverse effects of topiramate.*

Paresthesia
Fatigue
Nausea
Anorexia
Difficulty with memory
Weight decrease
Taste perversion
Diarrhea

Silberstein
et al26

Brandes
et al27

Diener
et al30

Rapoport
et al34

Silberstein
et al35

59
14
20
16
9
12
13
NR

59
17
12
16
12
13
10
13

55
19
13
17
4
7
5
NR

19.1
9.9
5.3
1.3
3.9
4.6
NR
5.9

28.8
11.9
8.8
5.0
6.9
NR
9.4
NR

Note: *As reported for daily dose of 100 mg, all numbers are reported as a percentage.
Abbreviation: NR, not reported.
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The UK Epilepsy and Pregnancy Register report that
14.3% of infants exposed to topiramate monotherapy
were small for gestational age. The effects appear to
be additive with other antiepileptic drugs such that
19.4% of babies exposed to topiramate and additional
antiepileptic drugs were small for gestational age.38
Adelman and colleagues conducted an analysis of the safety and tolerability data from more
than 1500 patients that participated in the 4 controlled trials that were examining the use of topiramate for migraine prevention.26,27,30,39 All four trials
were randomized, double-blind, placebo-controlled,
parallel-group studies examining the use of topiramate in migraine prevention. The early pilot trial
was not published. Three of the four studies were
pivotal trials, the fourth study was a pilot study conducted in the United States. The studies occurred in
111 centers across the United States and 70 centers
throughout Australia, Canada, Denmark, Finland,
France, Germany, Italy, Korea, the Netherlands,
South Africa, Spain, Sweden, Taiwan, and the United
Kingdom. The authors included all patients who took
at least one dose of medication during the doubleblind phase of all four studies. The authors’ safety
assessments were conducted from reports of adverse
events, results of clinical laboratory tests, vital sign
measurements, changes in body mass index (BMI)
and body weight, and neurological findings. Clinical
visits occurred two or three times during the titration phase and every 28 days during the maintenance
phase. Laboratory tests, vital signs and body weight
were recorded at every clinical visit.39
The most common topiramate related adverse
events were paresthesia, fatigue, nausea, anorexia,
dizziness, diarrhea, weight decrease, difficulty with
concentration/attention and somnolence.39 Overall,
there was a dose-dependent relationship between
the incidence of adverse events and topiramate dose.
For patients receiving placebo, 50, 100, or 200 mg/
day of topiramate, the incidence of adverse events
that led to a dose reduction or temporary pause in
the study was 12% for placebo, 15% for 50 mg, 20%
for 100 mg and 24% for 200 mg. A serious adverse
event that investigators considered unlikely to have
been a result of the treatment occurred in 2% of the
topiramate patients and 3% of the placebo patients.
Only two patients reported metabolic acidosis.
One suicide-related event was reported during the
162

open-label extension phase. No deaths were reported.
After analyzing the laboratory data, the researchers discovered a dose-dependent decrease in
serum-bicarbonate levels. They also observed dosedependent increases in serum chloride levels.39 Renal
calculus was documented in eleven patients. No cases
of glaucoma, oligohydrosis/hyperthermia, or hyperammonemia were reported in any of the four studies. No clinically significant changes in vital signs
or change in neurological function was reported. A
significant decrease in mean body weight from baseline to the last recorded measurement was observed.
Significant dose-dependent changes in body weight
from baseline also occurred. The study reports that
43% of patients, who received topiramate at any dose,
lost 1 to 6% of their initial body weight. Paresthesias
accounted for 51% of all topiramate related adverse
events for patients receiving 100 mg/day. Cognitive
adverse events, which the authors defined as confusion, psychomotor slowing, difficulty with memory,
difficulty with concentration/attention, and speech
or language problems, occurred in 22% of patients
receiving 100 mg/day. The incidence of adverse
events and discontinuation because of adverse events
was higher in the titration phase versus the maintenance phase of the studies. The analysis concluded
that topiramate is tolerated better at doses of 100 mg/
day than 200 mg/day when used for the prevention
of migraine. The authors also suggest titrating to the
target dose in increments of 25 mg per week. They
also recommend a 2 to 3 month trial of topiramate at
the target therapeutic level may be required before the
maximal benefit is noticed.39
A small, non-randomized, prospective, open-label
study at a single center in South Korea investigated
the relationship between side effects and drug efficacy of topiramate in migraine prevention.40 The
researchers included 118 patients who participated in
a 4-week screening phase, a 4-week titration phase
to 100 mg/day, and a 20-week maintenance phase.
They included subjects with more than 3 migraine
episodes per month. Headache improvement was
defined as a reduction in headache days of 50% or
more. Patients reporting paresthesia (n = 73) reported
fewer headache days then the patients not experiencing paresthesia (n = 60) both at 3 months (P = 0.026)
and 6 months (P = 0.002). The patients with paresthesia also demonstrated higher responder rates at
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3 and 6 months of 57.5% and 65.8%, respectively.
Compared to those who did not experience paresthesia (38.3% and 41.7%). The study investigators found
that patients usually experienced paresthesia during
the titration phase and that the paresthesia spontaneously subsided after about 2 to 3 months of treatment.
A decrease in the number of headache days did not
correlate with any other side effects.40 Based on their
data, the researchers concluded that patients who
experience paresthesia as a side effect displayed a
significantly better response to migraine prevention
with topiramate treatment. The authors stated that
the patient pool was not representative of the general
migraine population and suggest that additional studies should be conducted to prove their finding of a
possible link between paresthesia as a side effect and
efficacy of topiramate.40
Luykx et al compared topiramate related adverse
reactions in migraine patients and epilepsy patients
since both disorders share risk factors, symptoms,
and preventative medications.41 This meta-analysis
included four randomized controlled trials that used
topiramate as a comparator drug in epilepsy patients
and six randomized controlled trials that compared the
same doses of topiramate versus placebo in migraine
patients. The researcher’s primary objective was to
determine if migraineurs are more sensitive to adverse
drug reactions (ADRs) than epilepsy patients. All ten
studies included in the analysis reported percentages
of total adverse effects (AEs).41 The researchers discovered some adverse effects-AEs that were reported
in one group of patients and not the other. Both cognitive complaints and taste alteration were not reported
in the epilepsy trials, but were reported in some
migraine studies. Based on the six randomized controlled trials that the researchers examined, cognitive
complaints were reported for placebo, 50 mg, 100 mg,
and 200 mg at 5%, 11%, 13%, and 20% respectively.
Also respectively, alteration of taste was reported as
an adverse event at 1%, 14%, 7%, and 10%. Paresthesia was a side effect that was reported in both patient
groups. The frequency of experiencing paresthesia as
a side effect varied significantly between the disorders for all three dosages of topiramate. The authors
suggest central sensitization in migraine patients is a
possible mechanism as to why there are differences
between migraine patients and epilepsy patients when
they are given the same preventative drug.41
Journal of Central Nervous System Disease 2011:3

Another analysis of the data obtained from the three
pivotal randomized controlled trials that established
the efficacy of topiramate for migraine prevention was
conducted to determine the time course of adverse
events.42 Instead of focusing on discontinuation rates
as a measure of patient tolerability, the researchers
chose to examine when an AE was likely to occur and
the duration of the AE. The investigators defined the
number of days between the start of the double-blind
phase of the trials and the first reported occurrence of
the AE reported paresthesia by day 31, loss of appetite by day 34, fatigue by day 39, and any cognitive
symptom by day 45.42 The majority of AEs occurred
during the titration phase of the study. Throughout
the duration of the studies, patients receiving topiramate 100 mg/day experienced paresthesia an average
of 65 out of 182 days during the double-blind phase.
Approximately 2% of patients receiving topiramate
100 mg/day discontinued treatment during the study
period. Among the patients who discontinued, any
cognitive symptom was listed as the primary reason,
followed by fatigue and then paresthesia. Despite the
fact that paresthesia was experienced more frequently,
cognitive symptoms contributed more to treatment
discontinuation.42
The Washington State Toxicology Laboratory reported data regarding topiramate-positive
death investigation and impaired-driving cases.43
Topiramate-positive findings have increased in this
area because of the additional prescriptions for offlabel use of topiramate. From 1998 to 2004, the laboratory reported 63 death investigations, 68 suspected
impaired drivers, and one sexual assault case.43 The
mean reported serum topiramate concentration is
8.4 mg/L. In the death investigation subset, the
mean range for serum concentrations is 1.25 mg/L to
180 mg/L. In the impaired driving subset, the mean
range was from 1 to 20.4 mg/L. In most of the cases,
the person was positive for at least one other drug,
which was typically a narcotic analgesic. One of the
cases was ruled as a suicide and the cause of death
was ruled as quetiapine and topiramate toxicity. One
death was ruled as suicide by topiramate toxicity
alone. The subject’s serum concentration of topiramate was 49.2 mg/L.43 All of the people in the driving
cases were noted to be extremely impaired, unable
to verbalize coherently to the officer and displayed
marked confusion. Alcohol was a confounding factor
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in only 5 of the 68 cases. One report described a man
who slurred his words, and had coordination and
balance difficulties. His topiramate concentration was
reported as 3.7 mg/L. It was revealed that he was also
taking lamotrigine which can potentiate the actions of
topiramate.43
A case report presented information regarding
a 29 year old Caucasian female who developed
myoclonus and psychosis two weeks after a 25 mg
increase in her daily topiramate dose that she was
taking for migraine prophylaxis.44 The patient’s admitting diagnosis was catatonia and dehydration. She had
a history of cerebral palsy, migraines, chronic muscle
spasticity, constipation, and depression. The patient’s
mother stated that her daughter started experiencing
paranoid thoughts along with episodes of crying
and yelling. Afterwards, she became withdrawn,
anorexic, and started displaying jerking movements
of her arms and head. A thorough physical exam,
vital signs, and laboratory data was obtained. Laboratory data included a urine drug screen and pregnancy test, blood cell count, basic metabolic panel
and liver function test. All were unremarkable except
for a temperature of 38.2 ºC. Additional tests were
performed to rule out other causes of the patient’s
symptoms. A venous ultrasound of her legs, an electroencephalogram, and a computed tomography scan
of her brain did not provide any possible causes of
patient’s condition. A neurological exam was performed 24 hours after the patient was admitted to the
hospital. The exam revealed arm jerking, lip smacking, bilateral leg myoclonus that was induced by arm
and leg stimulation, severe bilateral ankle myoclonus
and absent deep-tendon reflexes. The patient’s home
medications were reconciled and no changes had
been made within the last year except for the addition of topiramate. It was concluded that a relationship existed between the patient’s condition and the
increase of her daily dose of topiramate. After being
in the hospital for 24 hours, her daily dose of topiramate was decreased to 50 mg. The daily dose was
decreased to 25 mg for four days, and then discontinued. The patient’s condition was stabilized and she
was discharged from the hospital 24 hours after topiramate therapy was discontinued. Follow-up visits
were conducted at three and six months. The patient
continued to experience depression with psychosis,
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but she has not experienced any additional episodes
of myoclonus.44
A case report presented data regarding a 37 year
old female with a history of bipolar disease who
tried to commit suicide by ingesting a large,
unknown amount of topiramate.29 She had been
prescribed topiramate 100 mg twice a day for her
bipolar disorder. She was also taking diazepam and
ibuprofen. The patient experienced movement in the
emergency room (ER) that was interpreted as seizure activity. The patient remained unresponsive
after receiving naloxone. She was intubated in order
to protect her airway. An arterial blood gas drawn in
the ER revealed nonanion gap metabolic acidosis.
Ethanol levels were not detectable. The patient was
in a coma and remained on a ventilator for 18 hours
without exhibiting agitation or paralysis and without requiring sedation medications. Her brainstem
reflexes, pupils, and response to painful stimuli were
all intact. Liver function tests, complete blood count
and coagulation studies were all within normal
limits. Even though she was comatose, the patient
did not exhibit respiratory depression or abnormal
vital signs. The results of a comprehensive urine
drug screen revealed topiramate, ibuprofen, and
10-hydroxytopiramate. Serum topiramate level was
measured to be 356.6 mcg/mL. Reference range at
this institution is 5−20 mcg/mL. The patient was
extubated on hospital day two. The authors report
that her speech was slurred for the next 24 hours.
She also displayed ataxia, nystagmus, and mild persistent somnolence. All of these signs and symptoms
gradually improved over the next 24 hours. Multiple
serum topiramate levels were drawn in order to calculate elimination toxicokinetics. First order linear
elimination was observed. The calculated serum
half-life was 16 hours. The patient was transferred
on hospital day 3 to an inpatient psychiatric facility. Her condition improved despite the fact she still
had metabolic acidosis and and elevated topiramate
levels.45

Patient preference

A randomized, double-blind, placebo-controlled
multicenter trial in 483 patients examined the ability of topiramate to improve the daily activities of
patients suffering from migraines.46 The duration of
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the trial was 13 months. The researchers utilized both
disease-specific and general instruments to quantify
the impact of migraine on daily activities. Patients
reported data from the MSQ and the Medical Outcomes Study 36-item Short-Form Health Survey
(SF-36). The secondary outcome instruments
included two activity-related MSQs (role restrictive
and role prevention) and two activity-related SF-36
forms (role physical and vitality).46 The improvement in scores for each questionnaire and survey
were calculated by measuring the area under the
curve during the maintenance phase compared to the
baseline. The results from the MSQ role restrictive
and role prevention domains demonstrated that
patients in this trial who received any dose of topiramate (50, 100, or 200 mg/day) displayed significant improvement in various measures of their
daily activities when compared to placebo. Some
examples of the influence of migraine on their daily
activities are present in their work, family, social
activities and the physical components of their wellbeing. A statistically significant improvement in the
SF-36 role physical domain was also reported in
patients receiving 100 mg or 200 mg/day of topiramate (P = 0.02). At baseline, SF-36 role physical mean score was 42.5 and 42.6 for the 100 mg/
day and 200 mg/day groups respectively. At endpoint, the scores had increased to 68.5 and 69.1. An
increase in the SF-36 role physical score is interpreted as an improvement in functional status within
the domains of physical function and role physical.
As the mean monthly migraine frequency decreased
for patients receiving 100 or 200 mg/day of topiramate, their functional status improved. None of the
groups showed a statistical significance with respect
to the SF-36 for vitality. The study provided information regarding the link between increase in productivity and decrease in migraine frequency.46
In a second randomized, placebo-controlled trial,
Silberstein et al examined the relationship between
quality of life and topiramate treatment for migraine
prevention. All subjects were required to have a baseline MIDAS exam.47 The trial examined numerous
prespecified secondary outcomes. The study found
that treatment with topiramate led to statistically significant increases when measuring the worst daily
headache severity, severity of photophobia, frequency
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of vomiting, phonophobia, photophobia, monthly
rate of unilateral pain, pulsatile pain, pain worsened
because of physical activity, and the role function-restrictive and emotional function domains of the MSQ.
The researchers also concluded that migraine therapy
prophylaxis improves health-related quality of life.
The improvement in their daily life is most likely a
result of decrease in the severity and frequency of
migraines.47
Another trial examined comorbidities in chronic
frequent headache patients (CFH) among the general
population. They also examined the impact of CFH
and comorbidity on quality of life.48 The study was
conducted in the Netherlands. The researchers placed
subjects in a CFH group or infrequent headache (IH)
group. The most prevalent comorbidities in both groups
were gastrointestinal disorders and musculoskeletal/
skin disorders. CFH subjects also reported more psychiatric and somatic disorders than the IH subjects.
The investigators measured quality of life by using
the RAND-36 which is described as a Dutch version
of Short-Form 36. They used the Cumulative Illness
Rating Scale (CIRS) to measure comorbidities. All
quality of life domains from the RAND-36 were negatively correlated to the CIRS score for comorbidity.
In summary, comorbidities were found to negatively
influence the quality of life from patient suffering
from infrequent or frequent headache.48

Place in therapy

Several factors are critical to the selection of topiramate in patients with migraine, including comorbidities and cost. Depression, obesity, anxiety, stroke,
epilepsy, sleep disorders, ulcer disease, asthma and
other pain disorders are commonly associated comorbidities in patients with migraine.49 One study evaluated the benefits and limitations of using monotherapy
versus polytherapy for migraine prevention in patients
with comorbid conditions.49 Risk of treating only
one condition, risk of choosing suboptimal medication, treatment timelines, and risk of poor tolerability
when a third condition is present are all presented as
limitations to monotherapy. Topiramate may also be
an appropriate choice in patients with both epilepsy
and migraine.
Cost-effectiveness of medication plays an important role in establishing its use in clinical practice for
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many patients. A study was conducted to examine the
cost-effectiveness of topiramate in migraine prevention. Since migraine often affects young individuals,
the economic burden to employers, health systems,
and society can be significant.50 The investigators
used a decision-analytical model to simulate model
outcomes for patients taking topiramate over a
specific duration. The model was composed of a
preventative module and an acute module. The
researchers also relied on pooled data obtained from
two US clinical trials. Their results estimated that
patients treated with topiramate 100 mg/day would
experience 4.15 migraines per month versus 6 per
month for untreated patients. The cost of acute treatment for topiramate-treated patients was about $27
less than the cost estimate for untreated patients.50
Additionally, the savings in acute care costs offset about 24% of the monthly cost of drug therapy.
topiramate treatment also prevented a loss of $51
of wages per month. Total savings related to treatment with topiramate off-set approximately 68% of
the $113 monthly cost of the topiramate prescription.
The number of quality-adjusted life years (QALYs)
gained was calculated to be 14.5 days over one year.
The cost-effectiveness ratio was determined to be
$26,191 per QALY.50 The authors suggest that the
cost of utilizing topiramate for migraine prophylaxis
makes it a reasonable option.50
Based on the European Federation of Neurological Societies (EFNS) guidelines, topiramate at a recommended daily dose of 25 to 100 mg per day is an
appropriate first line treatment option for the prevention of migraines with an “A” level of evidence.51 The
EFNS guidelines were last published in 2009. Level
A rating is defined by the EFNS as a therapeutic
intervention that is established as effective, ineffective, or harmful. A requirement to obtain the designated rating is the completion of at least one class
I study that is convincing, or two consistent class
II studies that are convincing.52 According to the
American Academy of Neurology (AAN) guidelines,
topiramate is recommended for preventative therapy
for migraines with a quality of evidence rating of C.
The AAN guidelines were last published in 2000.
Level C rating for quality of evidence is defined by
the AAN as a recommendation in the absence of relevant randomized controlled trials. They recommend
to give drugs with an evidence rating of C an adequate
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trial of 2 to 3 months.10 The last publication of the
evidenced-based guidelines from the American Headache Society was published in April, 2000. Topiramate
was not included in these guidelines. Data from two
of the large randomized controlled trials examining
the efficacy of topiramate in migraine prevention
were not published until 2004.26,27 Data from a third
large trial were not p ublished until 2007.29

Conclusions

Migraine headache is a prevalent, disabling
condition worldwide. In 2004, the number of
migraine suffers worldwide was reported to be
324.1 million people.53 Clinical evidence indicates
that topiramate is an effective agent in the prevention of migraine headache in patients with headaches that affect quality of life or who are intolerant
to rescue medications. It has a number of clinically
significant side effects, however few patients discontinue therapy as a result. It has gained popularity
over other agents in the prophylaxis and treatment
of migraine headache. Relative to other agents,
side effects are bothersome, but not disabling. In
addition, available evidence for its efficacy in
migraine provide reassurance to clinicians regarding its use in this setting. Effective use involves
careful dose titration and patient counseling on the
possibility of side effects.
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